Wegovy HD Side Effects: Complete Guide

Wegovy HD Side Effects: Complete Guide

On March 19, 2026, the U.S. FDA approved Wegovy HD, a 7.2 mg higher-dose semaglutide injection for weight loss and long-term weight maintenance in adults with obesity, or overweight with a weight-related condition, who have tolerated the 2.4 mg dose for at least 4 weeks and need additional weight loss. The 7.2 mg dose is also approved for adults in the EU and UK. That means an HD side-effects guide should not read like a generic Wegovy page.

This article focuses on the higher-dose product context so readers know what is different and what is shared with standard semaglutide safety guidance. Consult your healthcare provider before starting any medication.

What is Wegovy HD?

Wegovy HD is a higher-dose injectable semaglutide product. It still belongs to the GLP-1 receptor agonist class, but it represents a higher-dose option than previously approved Wegovy strengths.

Because the active ingredient is still semaglutide, much of the overall safety picture is familiar. But the higher-dose framing matters because some side effects may occur more often or feel more intense for some patients.

Common side effects of Wegovy HD

The FDA's March 19, 2026 announcement says the most common adverse reactions remained gastrointestinal, including:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal pain

These are the same side effects many patients already associate with semaglutide, but they were more common at the higher dose. In the STEP UP trial in adults with obesity, gastrointestinal side effects were reported by 70.8% of people on 7.2 mg, 61.2% on 2.4 mg and 42.8% on placebo. Most were mild to moderate.

Hair loss was also reported more often at the higher dose in the trials (5.8% on 7.2 mg versus 3.3% on 2.4 mg and 1.0% on placebo, mostly in women).

A side effect highlighted in the FDA announcement

The FDA also noted altered skin sensation—described as sensitivity, pain, or burning—as a common reaction that appeared more frequently at the higher Wegovy dosage than at lower doses. The announcement says these reports generally resolved on their own or after dose reduction, and that the FDA is still investigating this reaction. In STEP UP, dysaesthesia was reported by 22.9% of people on 7.2 mg, 6.0% on 2.4 mg and 0.5% on placebo. Tell your doctor if you notice it.

Why side effects happen

Semaglutide works by affecting appetite signaling and slowing gastric emptying. That helps with weight loss, but it also explains why digestive side effects are so common, especially during dose escalation.

With a higher-dose option such as Wegovy HD, the same mechanism can still create a stronger tolerability challenge for some patients.

Serious but less common side effects

Wegovy HD still carries the broader semaglutide safety warnings clinicians already monitor, including:

Pancreatitis

Severe persistent abdominal pain, sometimes spreading to the back, with or without vomiting, needs urgent medical help. Stop using Wegovy and get help straight away.

Gallbladder problems

Upper-abdominal pain, fever, jaundice (yellowing of the skin or eyes), or clay-coloured stools can be warning signs. Get medical help promptly.

Kidney problems linked to dehydration

Severe vomiting or diarrhoea can worsen dehydration and strain kidney function. Get medical help if you cannot keep fluids down.

Serious allergic reactions

Swelling of the face, lips, tongue or throat, trouble breathing, or severe rash should be treated as an emergency.

Low blood sugar

The risk is higher if you also take insulin or a sulfonylurea. Your doctor may need to lower those doses. Know the signs: shakiness, sweating, dizziness, confusion or a fast heartbeat.

Eye changes in people with diabetes

If you have diabetic eye disease (retinopathy), tell your doctor about any change in your vision.

Faster heart rate

Semaglutide can raise resting heart rate. Tell your doctor if you notice a racing or pounding heartbeat at rest.

Surgery and sedation

Tell your care team you take Wegovy before any surgery or procedure with anaesthesia or deep sedation, because of a risk of food in the stomach being breathed into the lungs.

Pregnancy

Do not use Wegovy if you are pregnant. Talk to your doctor if you are planning a pregnancy: because semaglutide stays in the body for weeks after the last dose, the US label advises stopping Wegovy at least 2 months before a planned pregnancy.

Boxed warning for thyroid C-cell tumors

Like other semaglutide products, Wegovy HD carries a US boxed warning based on rodent findings. Do not use it if you or a close relative has had medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your doctor about a lump in the neck, trouble swallowing, shortness of breath or a hoarse voice that does not go away.

Questions to ask your clinician about HD specifically

If you are considering Wegovy HD, ask:

1. Why are you recommending the 7.2 mg product instead of a lower dose?
2. Under the US label, the step to 7.2 mg is only after at least 4 weeks on 2.4 mg. When would that apply to me?
3. How should I respond if nausea or vomiting becomes hard to manage?
4. What should I watch for with the altered skin-sensation reports?
5. Would reducing the dose be an option if side effects become too disruptive?

Bottom line

Wegovy HD is not just standard Wegovy with a new headline. It is a higher-dose 7.2 mg semaglutide injection with a familiar semaglutide safety profile but an HD-specific discussion around tolerability, including gastrointestinal effects and the FDA's note about altered skin sensation appearing more often at the higher dose.

Your clinician can help you decide whether the extra dose intensity fits your treatment plan and risk tolerance. Consult your healthcare provider before starting any medication.

Sources

• FDA announcement of higher-dose semaglutide (Wegovy HD) approval, 19 March 2026: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide
• Wegovy US prescribing information (Novo Nordisk, revised June 2026): https://www.novo-pi.com/wegovy.pdf
• Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13:949-963: https://pubmed.ncbi.nlm.nih.gov/40961952/
• Novo Nordisk release: Wegovy HD (semaglutide 7.2 mg) approved in the US, 19 March 2026: https://www.biospace.com/press-releases/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss
• European Medicines Agency — Wegovy: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
• MedlinePlus — semaglutide injection: https://medlineplus.gov/druginfo/meds/a618008.html